IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
IRadimed CorporationNASDAQ: IRMD
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $403K (cash outflow) fell 89.1% year over year, behind the -59.7% change in trailing-twelve-month capital expenditures. Sequentially, it fell 16.4% from the prior quarter. Over 3 fiscal years it compounded at +60.6% a year.
Context
- Capital expenditures amounted to 9.3% of revenue in FY2025, down 1.7 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -89.1% toward the trailing-twelve-month pace of -59.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (7.77M) USD
- Year-over-year change
- +3.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.77M) | +3.0% |
| FY2024 | 2024-12-31 | (8.01M) | +0.0% |
| FY2023 | 2023-12-31 | (8.01M) | -327.0% |
| FY2022 | 2022-12-31 | (1.87M) | -152.8% |
| FY2021 | 2021-12-31 | (741.76K) | — |
Capital Expenditures vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's LTM Mar 2026 capital expenditures of $4.85M is the 10th largest of the 11 companies compared; the peer median is $17.84M.
- Its year-over-year change of -59.7% is the lowest of 11, against a peer median of -5.2%.
- Capital expenditures amounts to 5.6% of revenue for IRMD, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $408.02M | +30.0% | -0.8% | 14.3% | |
CTEVClaritev Corporation | LTM Mar 2026 | $137.5M | +8.7% | +13.0% | 14.0% |
| LTM Mar 2026 | $81.57M | -36.2% | +26.6% | 5.0% | |
| LTM Mar 2026 | $38.69M | -31.1% | -60.0% | 4.9% | |
| LTM Mar 2026 | $23.25M | +31.1% | -16.4% | 2.3% | |
| LTM Mar 2026 | $12.43M | -53.1% | +73.2% | 6.0% | |
| LTM Mar 2026 | $10.92M | -54.1% | -20.7% | 1.9% | |
| LTM Sep 2026 | $6.32M | +72.9% | -43.9% | 2.4% | |
| LTM Mar 2026 | $5.08M | -19.1% | -12.0% | 1.3% | |
| LTM Mar 2026 | $4.85M | -59.7% | +60.6% | 5.6% | |
| LTM Mar 2026 | $1.12M | +73.4% | -14.9% | 0.3% | |
| Peer median (excluding IRMD) | $17.84M | -5.2% | -13.4% | 3.6% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M |
| Depreciation & Amortization | 1.41M | 670.67K | 765.18K | 817.66K | 1.17M |
| Deferred Income Tax | 523.61K | 57.1K | (1.17M) | (697.65K) | 0 |
| Stock-Based Compensation | 1.46M | 1.39M | 2.19M | 2.52M | 2.92M |
| Change in Working Capital | (1.58M) | (5.06M) | (5.91M) | 3.75M | (4.35M) |
| Accounts Receivables | (575.54K) | (8.24M) | 841.91K | 1.76M | (3.03M) |
| Inventory | (393.32K) | (1.31M) | (7.47M) | 3.13M | (1.38M) |
| Accounts Payables | 30.41K | 1.12M | (216.44K) | (861.62K) | (76K) |
| Other Working Capital | (637.72K) | 3.37M | 932.43K | (277.58K) | 135K |
| Other Non-Cash Items | 119.04K | 148.74K | 402.32K | (3.02K) | 2.73M |
| Operating Cash Flow | 11.26M | 10.04M | 13.47M | 25.62M | 24.95M |
| Capital Expenditures | (741.76K) | (1.87M) | (8.01M) | (8.01M) | (7.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 1.39M | 500K | 0 | 0 | 0 |
| Other Investing Activities | (259.43K) | (1.05M) | (566.66K) | (811.75K) | (656K) |
| Investing Cash Flow | 648.24K | (1.37M) | (8.01M) | (8.82M) | (8.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 29.62K | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | (12.56M) | (13.22M) | (13.68M) | (15.04M) |
| Other Financing Activities | 24.43K | (147.27K) | (433.6K) | (688.16K) | (2.56M) |
| Financing Cash Flow | 24.43K | (12.71M) | (13.66M) | (14.34M) | (17.6M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.93M | (4.04M) | (8.2M) | 2.47M | (1.08M) |
| Free Cash Flow | 10.52M | 8.17M | 5.46M | 17.62M | 17.18M |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.